Abstract:e14574 Background: Immune checkpoint inhibitors (ICIs), targeting the programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have demonstrated impressive anti-tumor efficacy in multiple tumors, particularly non-small cell lung cancer (NSCLC). However, only a minority of patients could clinically benefit from the ICIs. Therefore, it is of vital clinical significance to explore underlying predictive biomarkers to identify to identify these most potentially ICIs-benefitable patients. Nuclear pore associated protein 1 ( NPAP1 ) encodes an protein is associated with the nuclear pore complex and has been previously reported as a potential prognostic biomarker for laryngeal, colorectal and lung cancers. However, its role in lung cancer immunotherapy remains unknown. Here we aimed to explore the association between NPAP1 and ICIs. Methods: 165 NSCLC patients from three public immunotherapy cohorts (Hellmann 2018, Miao 2018, and Rizvi 2015 cohort) were included to analyze the association between NPAP1 gene mutation and efficacy of ICI therapy. Genomic, survival and mRNA data of NSCLC patients from the Cancer Genome Atlas (TCGA) database was used to explore the potential mechanisms of anti-tumor immunity. Results: NSCLC patients with NPAP1 mutation were significantly associated with better PFS (HR = 0.37; 95% CI, 0.19-0.71; P = 0.002), objective response rate (ORR, 54.2% vs 28.4%; P = 0.048) and durable clinical benefit (DCB, 75.0% vs 42.6%; P = 0.003) after ICIs therapy, compared with those with wide-type NPAP1 . NPAP1 mutation were associated with increased TMB ( P < 0.001). In the multivariable Cox proportional hazards regression model adjusted by smoking status, PD-L1 expression and TMB, the association between NPAP1 mutation and PFS remained significant (HR = 0.46; 95% CI, 0.23-0.92; P = 0.028). In contrast, no association between NPAP1 mutation and OS (LUAD: P = 0.24 ; LUSC: P = 0.94) or PFS (LUAD: P = 0.3; LUSC: P = 0.72) was observed in TCGA datasets, suggesting that NPAP1 mutation may be a predictive but not a prognostic factor in ICI treatment for NSCLC patients. Based on CIBERSORT-inferred tumor infiltrating lymphocytes from TCGA, NPAP1 mutation was significantly associated with higher activated memory CD4+ T cell and CD8+ T cell. Moreover, NPAP1 mutation was associated with increased TMB ( P < 0.001) and neoantigen load ( P < 0.001) in TCGA. Conclusions: Our results demonstrated that NPAP1 mutation is an underlying classifier that could stratify patients with NSCLC for ICIs. The role of NPAP1 in immunotherapy is needed to be further studied.

Nuclear Localization of Human AP Endonuclease 1 (Hap1/ref-1) Associates with Prognosis in Early Operable Non-Small Cell Lung Cancer (NSCLC)

Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome

Human Apurinic Endonuclease 1 Expression in a Colorectal Adenoma-Carcinoma Sequence.

Expression and Subcellular Localization of Human AP Endonuclease 1 (hap1/ref‐1) Protein: a Basis for Its Role in Human Disease

Human AP Endonuclease 1 (HAP1) Protein Expression in Breast Cancer Correlates with Lymph Node Status and Angiogenesis.

Expression levels of the DNA repair enzyme HAP1 do not correlate with the radiosensitivities of human or HAP1-transfected rat cell lines

BAP1 is a Good Prognostic Factor in Advanced Non-Small Cell Lung Cancer.

A Role for the Human DNA Repair Enzyme HAP1 in Cellular Protection Against DNA Damaging Agents and Hypoxic Stress.

The Apurinic/apyrimidinic Endonuclease (Ape/ref-1) DNA Repair Enzyme is Elevated in Premalignant and Malignant Cervical Cancer.

NPAP1 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.

Prediction of Survival Prognosis of Non-Small Cell Lung Cancer by APE1 Through Regulation of Epithelial-Mesenchymal Transition

Association of Nuclear Annexin A1 with Prognosis of Patients with Esophageal Squamous Cell Carcinoma.

Small-molecule Inhibition of APE1 Induces Apoptosis, Pyroptosis, and Necroptosis in Non-Small Cell Lung Cancer

Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology

NAP1L1 is a Prognostic Biomarker and Contribute to Doxorubicin Chemotherapy Resistance in Human Hepatocellular Carcinoma

The APE1/REF-1 and the hallmarks of cancer

Mechanisms Underlying Regulation of Cell Cycle and Apoptosis by Hnrnp B1 in Human Lung Adenocarcinoma A549 Cells

YAP Mediates the Positive Regulation of Hnrnpk on the Lung Adenocarcinoma H1299 Cell Growth.

Human Α-Defensin-1 Inhibits Growth of Human Lung Adenocarcinoma Xenograft in Nude Mice

Transcriptional Up-Regulation of APE1/Ref-1 in Hepatic Tumor: Role in Hepatocytes Resistance to Oxidative Stress and Apoptosis

AP endonuclease 1: Biological updates and advances in activity analysis